1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hall, EJ; Pirro, JP; Roizin-Towle, L | 1 |
| Deacon, J; Holliday, S; Stratford, IJ; Walling, JM | 1 |
2 other study(ies) available for 1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol and Lung Neoplasms
| Article | Year |
|---|---|
Studies with bifunctional bioreductive drugs. II. Cytotoxicity assayed with A-549 lung carcinoma cells of human origin.
Topics: Antineoplastic Agents; Aziridines; Cell Line; Cell Survival; Humans; In Vitro Techniques; Lung Neoplasms; Misonidazole; Nitrofurans; Radiation-Sensitizing Agents | 1990 |
High uptake of RSU 1069 and its analogues melanotic melanomas.
Topics: Animals; Cell Line; Cell Membrane Permeability; Deoxyribonucleases; Drug Evaluation, Preclinical; Half-Life; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Microbial Collagenase; Misonidazole; Sarcoma, Experimental; Tissue Distribution; Trypsin; Tumor Cells, Cultured | 1989 |